Stock Movers: Alphabet, Qualcomm, Broadcom, AMD, Hims, Estee Lauder, and Others
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 05 2026
0mins
Should l Buy NVO?
Source: Barron's
- Market Trends: Stocks experienced a decline on Thursday, continuing a downward trend in the market.
- Tech Sector Impact: The selloff in tech stocks has persisted for three consecutive days.
- Earnings Report Influence: The downturn follows the quarterly earnings report from Alphabet, Google's parent company.
- Investor Sentiment: The negative reaction to the earnings report has contributed to the overall market decline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 39.780
Low
42.00
Averages
54.67
High
70.00
Current: 39.780
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BofA Nearly Doubles HIMS Price Target to $23 Following Novo Deal
- Price Target Surge: BofA has nearly doubled its price target for HIMS from $12.5 to $23, upgrading its rating from ‘Underperform’ to ‘Neutral’, indicating a significant boost in market confidence towards the company.
- Litigation Risk Mitigated: The dropping of the patent infringement lawsuit by Novo Nordisk is viewed as a “clear positive” for the telehealth operator, alleviating legal burdens and creating a more favorable environment for HIMS's future growth.
- Positive Market Reaction: Following the announcement, HIMS shares rose nearly 5%, while Novo shares dipped 1%, reflecting strong investor optimism for HIMS, with retail sentiment trending towards ‘extremely bullish’ territory.
- Partnership Agreement Details: HIMS and Novo have partnered to offer Ozempic and Wegovy at self-pay prices on HIMS's platform, discontinuing the advertisement of compounded GLP-1 products, a strategic shift expected to enhance HIMS's market competitiveness.
See More
Market Update: Oil Price Drop and Tech Stock Upgrades
- Oil Price Fluctuations: U.S. benchmark WTI crude prices have fallen below $90 a barrel, despite being up over 50% year-to-date, indicating market optimism regarding improved U.S.-Iran relations, yet geopolitical risks continue to loom over oil prices.
- Tech Stock Rating Changes: Intuit was upgraded to buy from hold by Rothschild & Co Redburn, with its stock rising over 30% since late February, although it remains down 28.5% for the year, reflecting a recovery in market confidence in its software products.
- Cybersecurity Stock Bounce: Morgan Stanley upgraded CrowdStrike from hold to buy, with its stock up over 20% from last month's low, highlighting the positive impact of AI technology on the cybersecurity sector and indicating optimistic market expectations for future growth.
- Hewlett Packard Enterprise's Positive Outlook: Despite memory cost pressures, the company raised its full-year earnings outlook, with reported quarterly revenues slightly below expectations but gross margins and adjusted EPS exceeding forecasts, demonstrating strong demand in the data center buildout.
See More
Latest Wall Street Rating Updates
- BofA Downgrades Qualcomm: Bank of America has downgraded Qualcomm from neutral to underperform with a price target of $145, citing lukewarm projected sales and EPS growth of only 2% and 1% CAGR from 2025 to 2028, significantly lagging the semiconductor sector's expected 17% growth.
- Deutsche Bank Upgrades Teladoc: Deutsche Bank upgraded Teladoc from hold to buy, highlighting an attractive risk/reward profile due to compelling valuation and a deliverable strategy for its BetterHelp business, indicating a strong potential for future growth.
- TD Cowen Upgrades Rivian: TD Cowen upgraded Rivian from hold to buy, projecting full-scale demand for its R2 model to reach between 212,000 and 335,000 units, suggesting significant upside potential against 2027 consensus estimates.
- Morgan Stanley Reiterates Microsoft Overweight: Morgan Stanley reiterated its overweight rating on Microsoft, emphasizing the readiness of its Office product suite for the upcoming Agentic AI offerings, with general availability expected on May 1, 2026, priced at $99 per user per month.
See More
Novo Nordisk Faces Increased Competitive Pressure
- Increased Competitive Pressure: TD Cowen downgraded Novo Nordisk from buy to hold, indicating that the company faces heightened pressure due to intensifying competition and looming patent risks for semaglutide.
- Price Target Reduction: Analyst Michael Nedelcovych lowered the price target for Novo Nordisk from $45 to $42, implying only a 6% potential upside, reflecting market concerns about the company's future performance.
- Declining Performance: Novo Nordisk's shares have dropped 22% this year and 50% over the past 12 months, indicating a weakening competitive position, particularly with lagging Ozempic prescriptions.
- Patent Risk Emergence: While the semaglutide patent is secured until 2032, its expiration in several countries this month is expected to weigh on investor sentiment, especially as branded competition intensifies.
See More
Hims & Hers Stock Upgraded Amid Novo Nordisk Deal
- Rating Upgrade: Citigroup upgraded Hims & Hers from 'Sell' to 'Neutral', raising its price target from $13.25 to $24, implying a 7% upside from the last close, indicating that the partnership with Novo Nordisk significantly reduces risk for the company.
- Demand Potential Unlocked: Needham upgraded the stock from 'Hold' to 'Buy' with a $30 price target, suggesting a 34% upside, believing that the Novo Nordisk partnership fundamentally changes the company's weight-loss business and overall growth algorithm.
- Short Sellers Hit Hard: The stock's surge caused short sellers to incur approximately $546 million in losses in a single day, reflecting a market reassessment of the company's outlook, with current short interest at $1.39 billion, representing 42.83% of the float.
- FDA Welcomes Partnership: FDA Commissioner Marty Makary expressed support for the deal on social media, stating that Hims will cease advertising unapproved compounded drugs and instead sell FDA-approved products, ensuring affordability while adhering to FDA guidelines.
See More
Argosy Investors Q4 Moves: New Positions and Exits
- New Investment Position: Argosy Investors acquired shares in Floor & Décor (FND) during Q4, noting that the company's current EBIT margins are approximately 30% below pre-COVID long-term levels, and anticipates margins will scale towards the low-to-mid-teens as the store base expands, enhancing profitability and market competitiveness.
- Exit from Unfavorable Investment: The fund sold its position in Novo Nordisk (NVO) after a brief holding period due to findings from further due diligence indicating a disadvantageous competitive situation, demonstrating caution and flexibility in investment decisions.
- Increased Confidence in Holdings: Argosy also strengthened its position in Endava (DAVA) during Q4, believing that its share price performance is largely company-specific and that there is a significant chance of mean reversion if DAVA can demonstrate inflecting organic revenue growth, indicating confidence in its future growth potential.
- Market Dynamics Insight: In analyzing market dynamics, Argosy is attentive to Novo Nordisk's competitive landscape and market pressures, particularly in light of positive mid-stage trial results for its obesity drug in China, showcasing keen insights into industry trends.
See More
BofA Nearly Doubles HIMS Price Target to $23 Following Novo Deal
- Price Target Surge: BofA has nearly doubled its price target for HIMS from $12.5 to $23, upgrading its rating from ‘Underperform’ to ‘Neutral’, indicating a significant boost in market confidence towards the company.
- Litigation Risk Mitigated: The dropping of the patent infringement lawsuit by Novo Nordisk is viewed as a “clear positive” for the telehealth operator, alleviating legal burdens and creating a more favorable environment for HIMS's future growth.
- Positive Market Reaction: Following the announcement, HIMS shares rose nearly 5%, while Novo shares dipped 1%, reflecting strong investor optimism for HIMS, with retail sentiment trending towards ‘extremely bullish’ territory.
- Partnership Agreement Details: HIMS and Novo have partnered to offer Ozempic and Wegovy at self-pay prices on HIMS's platform, discontinuing the advertisement of compounded GLP-1 products, a strategic shift expected to enhance HIMS's market competitiveness.
See More
Market Update: Oil Price Drop and Tech Stock Upgrades
- Oil Price Fluctuations: U.S. benchmark WTI crude prices have fallen below $90 a barrel, despite being up over 50% year-to-date, indicating market optimism regarding improved U.S.-Iran relations, yet geopolitical risks continue to loom over oil prices.
- Tech Stock Rating Changes: Intuit was upgraded to buy from hold by Rothschild & Co Redburn, with its stock rising over 30% since late February, although it remains down 28.5% for the year, reflecting a recovery in market confidence in its software products.
- Cybersecurity Stock Bounce: Morgan Stanley upgraded CrowdStrike from hold to buy, with its stock up over 20% from last month's low, highlighting the positive impact of AI technology on the cybersecurity sector and indicating optimistic market expectations for future growth.
- Hewlett Packard Enterprise's Positive Outlook: Despite memory cost pressures, the company raised its full-year earnings outlook, with reported quarterly revenues slightly below expectations but gross margins and adjusted EPS exceeding forecasts, demonstrating strong demand in the data center buildout.
See More
Latest Wall Street Rating Updates
- BofA Downgrades Qualcomm: Bank of America has downgraded Qualcomm from neutral to underperform with a price target of $145, citing lukewarm projected sales and EPS growth of only 2% and 1% CAGR from 2025 to 2028, significantly lagging the semiconductor sector's expected 17% growth.
- Deutsche Bank Upgrades Teladoc: Deutsche Bank upgraded Teladoc from hold to buy, highlighting an attractive risk/reward profile due to compelling valuation and a deliverable strategy for its BetterHelp business, indicating a strong potential for future growth.
- TD Cowen Upgrades Rivian: TD Cowen upgraded Rivian from hold to buy, projecting full-scale demand for its R2 model to reach between 212,000 and 335,000 units, suggesting significant upside potential against 2027 consensus estimates.
- Morgan Stanley Reiterates Microsoft Overweight: Morgan Stanley reiterated its overweight rating on Microsoft, emphasizing the readiness of its Office product suite for the upcoming Agentic AI offerings, with general availability expected on May 1, 2026, priced at $99 per user per month.
See More
Novo Nordisk Faces Increased Competitive Pressure
- Increased Competitive Pressure: TD Cowen downgraded Novo Nordisk from buy to hold, indicating that the company faces heightened pressure due to intensifying competition and looming patent risks for semaglutide.
- Price Target Reduction: Analyst Michael Nedelcovych lowered the price target for Novo Nordisk from $45 to $42, implying only a 6% potential upside, reflecting market concerns about the company's future performance.
- Declining Performance: Novo Nordisk's shares have dropped 22% this year and 50% over the past 12 months, indicating a weakening competitive position, particularly with lagging Ozempic prescriptions.
- Patent Risk Emergence: While the semaglutide patent is secured until 2032, its expiration in several countries this month is expected to weigh on investor sentiment, especially as branded competition intensifies.
See More
Hims & Hers Stock Upgraded Amid Novo Nordisk Deal
- Rating Upgrade: Citigroup upgraded Hims & Hers from 'Sell' to 'Neutral', raising its price target from $13.25 to $24, implying a 7% upside from the last close, indicating that the partnership with Novo Nordisk significantly reduces risk for the company.
- Demand Potential Unlocked: Needham upgraded the stock from 'Hold' to 'Buy' with a $30 price target, suggesting a 34% upside, believing that the Novo Nordisk partnership fundamentally changes the company's weight-loss business and overall growth algorithm.
- Short Sellers Hit Hard: The stock's surge caused short sellers to incur approximately $546 million in losses in a single day, reflecting a market reassessment of the company's outlook, with current short interest at $1.39 billion, representing 42.83% of the float.
- FDA Welcomes Partnership: FDA Commissioner Marty Makary expressed support for the deal on social media, stating that Hims will cease advertising unapproved compounded drugs and instead sell FDA-approved products, ensuring affordability while adhering to FDA guidelines.
See More
Argosy Investors Q4 Moves: New Positions and Exits
- New Investment Position: Argosy Investors acquired shares in Floor & Décor (FND) during Q4, noting that the company's current EBIT margins are approximately 30% below pre-COVID long-term levels, and anticipates margins will scale towards the low-to-mid-teens as the store base expands, enhancing profitability and market competitiveness.
- Exit from Unfavorable Investment: The fund sold its position in Novo Nordisk (NVO) after a brief holding period due to findings from further due diligence indicating a disadvantageous competitive situation, demonstrating caution and flexibility in investment decisions.
- Increased Confidence in Holdings: Argosy also strengthened its position in Endava (DAVA) during Q4, believing that its share price performance is largely company-specific and that there is a significant chance of mean reversion if DAVA can demonstrate inflecting organic revenue growth, indicating confidence in its future growth potential.
- Market Dynamics Insight: In analyzing market dynamics, Argosy is attentive to Novo Nordisk's competitive landscape and market pressures, particularly in light of positive mid-stage trial results for its obesity drug in China, showcasing keen insights into industry trends.
See More
